Skip to content

Efficacy and safety of combined laryngeal-tracheal-oesophageal-thyroid multi-organ cluster transplantation for the treatment of patients after total laryngectomy: a prospective, single-centre,open-label, non-randomised controlled clinical study

Efficacy and safety of combined laryngeal-tracheal-oesophageal-thyroid multi-organ cluster transplantation for the treatment of patients after total laryngectomy: a prospective, single-centre,open-label, non-randomised controlled clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084130
Enrollment
Unknown
Registered
2024-05-10
Start date
2024-05-13
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal transplantation

Interventions

Test Group:Laryngal-tracheal transplantation was performed after total laryngectomy
Control Group:Total Laryngectomy alone (within the same period of time)

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for Test group: To be eligible for the study, participants had to meet the following criteria at the same time: a. Study participants who underwent total laryngectomy due to a variety of causes (including but not limited to advanced laryngeal cancer, laryngeal cancer recurrence, hypopharyngeal and cervical esophageal cancer, tongue cancer, trauma, postoperative recurrence of advanced thyroid cancer, etc.); b. Study participants under 75 years old (including 75 years old) with urgent needs for voice function; c. Study participants with good general condition or combined with hypertension, diabetes, coronary heart disease, thyroid dysfunction, liver and kidney dysfunction and other basic diseases who were feasible for surgery after multidisciplinary consultation evaluation; d. Participants who are willing to take life-long immunosuppressive drugs and the risks involved or who have previously required life-long immunosuppressive drugs for other causes (e.g., other organ transplantation, certain rheumatic diseases, etc.); e. Study participants and their family members (main accompany) have certain language, reading, writing and communication skills to facilitate the completion of the questionnaire; f. Voluntarily participated in this study after informed consent, agreed to undergo laryngal-tracheal transplantation, and could return to the hospital on time for follow-up. 2. Inclusion criteria for Control group: To be eligible for the study, participants had to meet the following criteria at the same time: a. Study participants who required total laryngectomy for a variety of causes (including but not limited to advanced laryngeal cancer, laryngeal cancer recurrence, hypopharyngeal and cervical esophageal cancer, tongue cancer, trauma, postoperative recurrence of advanced thyroid cancer, etc).; b. Under the age of 75 years old (including 75 years old); c. The study participants and their family members (the main accompany) have certain language, reading, writing and communication skills to facilitate the filling of the questionnaire; d. Voluntarily participated in this study after informed consent, agreed to undergo total laryngectomy, and could return to the hospital on time for follow-up.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria for Test group: Study participants were ineligible if they met any of the following criteria: a. Over 75 years old of age, no urgent need for laryngeal function such as voice function; b. Poor general condition, unable to tolerate laryngotracheal transplantation and lifelong immunosuppressive therapy; c. Patients are still living with tumor after total laryngectomy (including but not limited to local recurrence, distant metastasis, and new tumors in other sites); d. Patients with psychiatric or psychological disorders prior to total laryngectomy. 2. Exclusion criteria for Control group: Study participants were ineligible if they met any of the following criteria: a. older than 75 years old of age; b. Patients are still living with tumor after total laryngectomy (including but not limited to local recurrence, distant metastasis, and new malignant tumors in other sites); c. Patients with psychiatric or psychological disorders prior to total laryngectomy.

Design outcomes

Primary

MeasureTime frame
Overall Survival;Rrecovery time of Voice function;

Secondary

MeasureTime frame
Disease Free Survival;Graft Survival;Postoperative adverse event incidence rate;Quality of Survival (European five-dimensional Health Scale score,Anderson Symptom Assessment Scale( Head and Neck) score, etc.);Psychological State (Self-rating Anxiety Scale score, Self-rating Depression Scale score, etc.);Primary Caregiver Psychological Status (Sense of Coherence);Recovery time of Swallowing function;Rate of olfactory change;

Countries

China

Contacts

Public ContactChen Fei

West China Hospital, Sichuan University

hxchenfei@163.com+86 189 8060 2124

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026